Neocolipor

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

E. coli adhesin F4 (F4ab, F4ac, F4ad), E. coli adhesin F5, E. coli adhesin F6, E. coli adhesin F41

Available from:

Boehringer Ingelheim Vetmedica GmbH

ATC code:

QI09AB02

INN (International Name):

Neonatal piglet colibacillosis vaccine (inactivated)

Therapeutic group:

Sows; Sows (nullipar)

Therapeutic area:

Immunologicals for suidae, Inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia)

Therapeutic indications:

Намаляване на неонаталната ентеротоксикоза на прасенца, причинено от Е. coli щамове, експресиращи адхезините F4ab, F4ac, F4ad, F5, F6 и F41, през първите дни от живота.

Product summary:

Revision: 14

Authorization status:

упълномощен

Authorization date:

1998-04-14

Patient Information leaflet

                                16
B. ЛИСТОВКА
17
ЛИСТОВКА:
NEOCOLIPOR
1.
ИМЕ И ПОСТОЯННИЯ АДРЕС НА УПРАВЛЕНИЕ
НА ПРИТЕЖАТЕЛЯ НА
ЛИЦЕНЗА ЗА УПОТРЕБА И НА
ПРОИЗВОДИТЕЛЯ, АКО ТЕ СА РАЗЛИЧНИ
ЛИЦА
ПРИТЕЖАТЕЛ НА ЛИЦЕНЗА ЗА УПОТРЕБА
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
ГЕРМАНИЯ
ЛИЦЕ ОТГОВОРНО ЗА ОСВОБОЖДАВАНЕ НА
ПАРТИДАТА
Boehringer Ingelheim Animal Health France SCS
Laboratoire Porte des Alpes
Rue de l’Aviation
F-69800 SAINT PRIEST
ФРАНЦИЯ.
2.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Neocolipor суспензия за инжектиране
3.
СЪДЪРЖАНИЕ НА АКТИВНИТЕ СУБСТАНЦИИ И
ПОМОЩНИТЕ ВЕЩЕСТВА
за доза от 2 ml:
E. coli адхезин F4 (F4ab, F4ac, F4ad), най-много
.................................................................. 2.1
SA.U*
E. coli адхезин F5, най-много
.................................................................................................
1.7 SA.U*
E. coli адхезин F6, най-много
.................................................................................................
1.4 SA.U*
E. coli адхезин F41, най-много
...............................................................................................
1.7 SA.U*
*:
1
SA.U: количество, достатъчно за
постигане на аглутиниращи титри на
антителата от 1 log
10
при морски свинчета.
Аджувант:
Алуминии (като хидриксид)
.........................................................................................................
1.4 mg
4.
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
Редуциране на неонаталната
ентеротоксикоза при прасета, през

                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Neocolipor суспензия за инжектиране
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
АКТИВНА СУБСТАНЦИЯ(И):
за доза от 2 ml:
E. coli адхезин F4 (F4ab, F4ac, F4ad), най-малко
....................................................................
2.1 SA.U*
E. coli адхезин F5, най-малко
...................................................................................................
1.7 SA.U*
E. coli адхезин F6, най-малко
...................................................................................................
1.4 SA.U*
E. coli адхезин F41, най-малко
.................................................................................................
1.7 SA.U*
*:
1
SA.U: количество, достатъчно за
постигане на аглутиниращи титри на
антителата от 1 log
10
при морски свинчета.
АДЖУВАНТ:
Алуминий (като хидроксид)
......................................................................................................
1.4 mg
ЕКСЦИПИЕНТ
Тиомерсал
....................................................................................................................................
0.2 mg
За пълен списък на помощните вещества,
виж т. 6.1.
3.
ФАРМАЦЕВТИЧНА ФОРМА
Суспензия за инжектиране.
4.
КЛИНИЧНИ ДАННИ
4.1
ВИДЪТ ЖИВОТНИ, ЗА КОИТО Е ПРЕДНАЗНАЧЕН
Прасета (свине и ремонтни прасета).
4.2
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ ЗА ОТДЕЛНИТЕ
ВИДОВЕ ЖИВОТНИ
_ _
Редуциране на неонаталната
ентероток
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 16-06-2020
Public Assessment Report Public Assessment Report Spanish 17-02-2021
Patient Information leaflet Patient Information leaflet Czech 16-06-2020
Public Assessment Report Public Assessment Report Czech 17-02-2021
Patient Information leaflet Patient Information leaflet Danish 16-06-2020
Public Assessment Report Public Assessment Report Danish 17-02-2021
Patient Information leaflet Patient Information leaflet German 16-06-2020
Public Assessment Report Public Assessment Report German 17-02-2021
Patient Information leaflet Patient Information leaflet Estonian 16-06-2020
Public Assessment Report Public Assessment Report Estonian 17-02-2021
Patient Information leaflet Patient Information leaflet Greek 16-06-2020
Public Assessment Report Public Assessment Report Greek 17-02-2021
Patient Information leaflet Patient Information leaflet English 16-06-2020
Public Assessment Report Public Assessment Report English 17-02-2021
Patient Information leaflet Patient Information leaflet French 16-06-2020
Public Assessment Report Public Assessment Report French 17-02-2021
Patient Information leaflet Patient Information leaflet Italian 16-06-2020
Public Assessment Report Public Assessment Report Italian 17-02-2021
Patient Information leaflet Patient Information leaflet Latvian 16-06-2020
Public Assessment Report Public Assessment Report Latvian 17-02-2021
Patient Information leaflet Patient Information leaflet Lithuanian 16-06-2020
Summary of Product characteristics Summary of Product characteristics Lithuanian 16-06-2020
Public Assessment Report Public Assessment Report Lithuanian 17-02-2021
Patient Information leaflet Patient Information leaflet Hungarian 16-06-2020
Summary of Product characteristics Summary of Product characteristics Hungarian 16-06-2020
Public Assessment Report Public Assessment Report Hungarian 17-02-2021
Patient Information leaflet Patient Information leaflet Maltese 16-06-2020
Public Assessment Report Public Assessment Report Maltese 17-02-2021
Patient Information leaflet Patient Information leaflet Dutch 16-06-2020
Public Assessment Report Public Assessment Report Dutch 17-02-2021
Patient Information leaflet Patient Information leaflet Polish 16-06-2020
Public Assessment Report Public Assessment Report Polish 17-02-2021
Patient Information leaflet Patient Information leaflet Portuguese 16-06-2020
Summary of Product characteristics Summary of Product characteristics Portuguese 16-06-2020
Public Assessment Report Public Assessment Report Portuguese 17-02-2021
Patient Information leaflet Patient Information leaflet Romanian 16-06-2020
Public Assessment Report Public Assessment Report Romanian 17-02-2021
Patient Information leaflet Patient Information leaflet Slovak 16-06-2020
Public Assessment Report Public Assessment Report Slovak 17-02-2021
Patient Information leaflet Patient Information leaflet Slovenian 16-06-2020
Summary of Product characteristics Summary of Product characteristics Slovenian 16-06-2020
Public Assessment Report Public Assessment Report Slovenian 17-02-2021
Patient Information leaflet Patient Information leaflet Finnish 16-06-2020
Public Assessment Report Public Assessment Report Finnish 17-02-2021
Patient Information leaflet Patient Information leaflet Swedish 16-06-2020
Public Assessment Report Public Assessment Report Swedish 17-02-2021
Patient Information leaflet Patient Information leaflet Norwegian 16-06-2020
Summary of Product characteristics Summary of Product characteristics Norwegian 16-06-2020
Patient Information leaflet Patient Information leaflet Icelandic 16-06-2020
Summary of Product characteristics Summary of Product characteristics Icelandic 16-06-2020
Patient Information leaflet Patient Information leaflet Croatian 16-06-2020
Public Assessment Report Public Assessment Report Croatian 17-02-2021

View documents history